TY - JOUR
T1 - βIII-tubulin overexpression in cancer
T2 - Causes, consequences, and potential therapies
AU - Kanakkanthara, Arun
AU - Miller, John H.
N1 - Funding Information:
This work was supported by a Foundation for Women's Cancer Genentech Ovarian Cancer Young Investigator Career Development Award (to A.K.), and a Wallace and Evelyn Simmers Career Development Award for Ovarian Cancer Research (to A.K.), a Mayo Clinic Ovarian Cancer SPORE Developmental Award (to A.K.), and a Mayo Clinic Ovarian Cancer SPORE Career Enhancement Award (to A.K.). Support was also received from the Cancer Society of New Zealand and Wellington Medical Research Foundation (to J.H.M.).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12
Y1 - 2021/12
N2 - Class III β-tubulin (βIII-tubulin) is frequently overexpressed in human tumors and is associated with resistance to microtubule-targeting agents, tumor aggressiveness, and poor patient outcome. Understanding the mechanisms regulating βIII-tubulin expression and the varied functions βIII-tubulin may have in different cancers is vital to assess the prognostic value of this protein and to develop strategies to enhance therapeutic benefits in βIII-tubulin overexpressing tumors. Here we gather all the available evidence regarding the clinical implications of βIII-tubulin overexpression in cancer, describe factors that regulate βIII-tubulin expression, and discuss current understanding of the mechanisms underlying βIII-tubulin-mediated resistance to microtubule-targeting agents and tumor aggressiveness. Finally, we provide an overview of emerging therapeutic strategies to target tumors that overexpress βIII-tubulin.
AB - Class III β-tubulin (βIII-tubulin) is frequently overexpressed in human tumors and is associated with resistance to microtubule-targeting agents, tumor aggressiveness, and poor patient outcome. Understanding the mechanisms regulating βIII-tubulin expression and the varied functions βIII-tubulin may have in different cancers is vital to assess the prognostic value of this protein and to develop strategies to enhance therapeutic benefits in βIII-tubulin overexpressing tumors. Here we gather all the available evidence regarding the clinical implications of βIII-tubulin overexpression in cancer, describe factors that regulate βIII-tubulin expression, and discuss current understanding of the mechanisms underlying βIII-tubulin-mediated resistance to microtubule-targeting agents and tumor aggressiveness. Finally, we provide an overview of emerging therapeutic strategies to target tumors that overexpress βIII-tubulin.
KW - Class III β-tubulin
KW - Colchicine
KW - Drug resistance
KW - Microtubule-targeting agents
KW - Paclitaxel
KW - Tumor aggressiveness
KW - Vinca alkaloids
UR - http://www.scopus.com/inward/record.url?scp=85112205136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112205136&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2021.188607
DO - 10.1016/j.bbcan.2021.188607
M3 - Review article
C2 - 34364992
AN - SCOPUS:85112205136
SN - 0304-419X
VL - 1876
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 2
M1 - 188607
ER -